The pathophysiology of pulmonary arterial hypertension (PAH) is distinguished by diminished generation of vasodilators, including prostacyclin and nitric oxide (NO), alongside the overexpression of vascular constrictors such as endothelin-1 and tromboxane. Here, EDN1 is linked to pulmonary arterial hypertension.